Pembrolizumab improved progression-free survival (PFS) and overall survival (OS) over best supportive care in patients with advanced hepatocellular carcinoma (HCC), according to the phase III KEYNOTE-240* trial, supporting its role as a treatment option for HCC in the second-line setting.
The poloxamer-based, temperature-sensitive, anti-adhesive agent Guardix-SG was effective and safe in the prevention of intra-abdominal adhesions and small bowel obstruction in gastric cancer patients after undergoing radical gastrectomy, a Korean study has shown.
Stenting prior to primary tumour resection (PTR) is effective against stage IV primary obstructing colorectal cancers (CRC), resulting in durable palliation and low perioperative morbidity, according to a recent Singapore study.
Vocinti® (vonoprazan), a first-in-class potassium-competitive acid blocker (P-CAB) is now available in Malaysia for use in Helicobacter pylori eradication therapy and erosive (reflux) oesophagitis treatment.
Individuals with type 2 diabetes mellitus (T2D) may be at risk of developing gastric cancer even after receiving Helicobacter pylori (H. pylori) eradication therapy, demonstrated a study from Hong Kong.
Initiating therapy with a combination of immune modulators (IM) and antitumour necrosis factor (anti-TNF) agents appears to reduce the incidence of therapeutic ineffectiveness in patients with Crohn’s disease (CD) but not those with ulcerative colitis (UC), a recent study has found.
Besifovir dipivoxil maleate has antiviral efficacy against chronic hepatitis B that is similar to that of tenofovir disoproxil fumarate but with a lower impact on bone and renal safety, as shown in the results of a phase III trial involving Asian patients.
Persistence to treatment with a tumour necrosis factor (TNF)‐α inhibitor for inflammatory bowel disease (IBD) appears to be lower among female than male patients, as reported in a recent study. Treatment discontinuation is driven mainly by side effects, the rate of which being higher in women than in men.
Exposure to corticosteroids in patients with autoimmune hepatitis (AIH) appears to contribute to increased risks of cataract, diabetes and bone fractures, a study has found. Notably, the fracture risk is elevated at low doses, while the risk of adverse events overall is dose-dependent and is reversible.
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Supplementation with oral nano vitamin D appears to moderate disease activity and severity grade of patients with active ulcerative colitis (UC), suggests a study, adding that this association is more evident in those achieving a target vitamin D level of 40 ng/mL.